About
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Current Value
$5.491 Year Return
Current Value
$5.491 Year Return
Key Details
Market Cap
$217.71M
P/E Ratio
-1.63
1Y Stock Return
-54.18%
1Y Revenue Growth
177.89%
Dividend Yield
0.00%
Price to Book
0.4
Strategies that include ITOS
Double maintains 1 strategies that include ITOS - iTeos Therapeutics, Inc.
Health Care Sector
Medium risk
$14.0K
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
346
Stock's related to ITOS
The stocks that are correlated to ITOS - iTeos Therapeutics, Inc. are NVAX, MTD, GEN, CDNA, NNI
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
N NVAXNovavax, Inc. | 53.18% | $900.73M | +26.13% | 0.00% |
| 50.09% | $22.83B | -14.74% | 0.00% | |
G GENGen Digital Inc. | 42.20% | $16.02B | +18.02% | 1.98% |
C CDNACareDx, Inc. | 41.83% | $962.75M | +77.24% | 0.00% |
N NNINelnet, Inc. | 40.97% | $3.87B | +13.92% | 1.07% |
A ADMAADMA Biologics, Inc. | 38.04% | $4.62B | +209.71% | 0.00% |
| 36.77% | $758.88M | -58.48% | 0.00% | |
| 36.52% | $2.64B | -6.13% | 0.00% | |
O OUSTOuster, Inc. | 36.43% | $434.97M | -19.02% | 0.00% |
| 35.50% | $5.19B | +131.52% | 0.00% | |
| 35.45% | $141.87M | -6.46% | 8.88% | |
I IMNMImmunome, Inc. | 35.21% | $542.57M | -69.20% | 0.00% |
| 34.66% | $12.87B | -22.34% | 0.00% | |
G GRVYGravity Co. Ltd. | 34.61% | $417.84M | -18.29% | 0.00% |
| 34.15% | $1.36B | -62.39% | 0.00% | |
| 33.36% | $1.19B | -26.04% | 0.00% | |
| 33.27% | $29.57B | -29.70% | 0.00% | |
A ALECAlector, Inc. | 32.92% | $108.00M | -81.08% | 0.00% |
| 32.51% | $5.80B | -14.26% | 4.63% | |
I INSGInseego Corp. | 32.48% | $110.15M | +174.91% | 0.00% |
ETF's related to ITOS
The ETFs that are correlated to ITOS - iTeos Therapeutics, Inc. are GNOM, IBB, CPRJ, XBI, ARKG
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 38.36% | $48.48M | 0.5% | |
| 37.64% | $5.70B | 0.45% | |
| 36.19% | $48.65M | 0.69% | |
X XBISPDR Biotech ETF | 36.04% | $5.06B | 0.35% |
| 34.41% | $987.53M | 0.75% | |
| 32.60% | $362.92M | 0.35% | |
| 32.13% | $229.13M | 0.58% | |
| 31.82% | $809.63M | 0.6% | |
| 30.58% | $1.09B | 0.56% | |
| 29.58% | $666.40M | 0.06% | |
| 29.57% | $110.09M | 0.6% | |
| 28.39% | $141.74M | 0.5% | |
| 28.30% | $10.93B | 0.24% | |
| 28.14% | $42.67M | 0.68% | |
| 28.12% | $1.98B | 0.2% | |
| 27.84% | $11.24B | 0.07% | |
| 27.84% | $16.19B | 0.04% | |
| 27.62% | $63.84B | 0.19% | |
| 27.55% | $2.25B | 0.25% | |
| 27.46% | $692.98M | 0.91% | |
News
Yahoo
WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the poster presentations of preclinical data on EOS-215, a potential best-in-class antibody targeting TREM2, and a novel small molecule inhibiting PTPN1/2 at the American Association for Cancer Research (AACR) Annual
Yahoo
The consensus price target hints at a 212.5% upside potential for iTeos Therapeutics (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Yahoo
iTeos Therapeutics ( NASDAQ:ITOS ) Full Year 2024 Results Key Financial Results Revenue: US$35.0m (up 178% from FY...
Yahoo
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025- Completed enrollment of second dose cohort of EOS-984 + pembrolizumab combination in ongoing Phase 1 trial- EOS-215 Phase 1 trial TRM-010 patient enrollment anticipated to begin in 2Q25- Cash balance and investment balance of $655.0 million as of December 31, 2024 expected to provide runway through 2027 WATERTOWN
SeekingAlpha
iTeos' Belrestotug shows efficacy in trials, backed by a strong cash runway. Learn why ITOS stock might thrive with strategic GSK collaboration.
Yahoo
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds